Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 2/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17809740 | 0.76 | FGFR4 (0.41) | LRRK2FGFR4CYP11B1CYP11B2KEAP1 | |
| SCHEMBL19368978 | 0.74 | FGFR4 (0.40) | LRRK2FGFR4CYP11B1CYP11B2KEAP1 | |
| SCHEMBL31601615 | 0.72 | USP30 (0.45) | LRRK2CYP11B1CYP11B2 | |
| SCHEMBL21255142 | 0.70 | FGFR4 (0.44) | LRRK2FGFR4TBK1PDE10AJAK2 | |
| SCHEMBL26112159 | 0.68 | OTUD7B (0.42) | CYP11B2MAPT | |
| SCHEMBL30993515 | 0.68 | EED (0.37) | CYP11B2PDE10AMAPTHSD17B10 | |
| SCHEMBL30480876 | 0.68 | OTUD7B (0.42) | CYP11B2MAPT | |
| SCHEMBL21254969 | 0.68 | MAPT (0.40) | ATMMAPTHSD17B10 | |
| SCHEMBL30480863 | 0.68 | MAPT (0.40) | ATMMAPTHSD17B10 | |
| SCHEMBL17785738 | 0.65 | DRD1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | LRRK2 1250/4885FGFR4 2821/4885CYP11B1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.